Veru Inc. is moving forward with its Phase 2b PLATEAU clinical trial, combining enobosarm with semaglutide for older obese patients. The trial aims to break the weight loss plateau seen in patients on GLP-1 RA. Results of the Phase 2b QUALITY trial showed promising outcomes for weight reduction. Veru’s financial report for Q1 FY2026 also shows positive trends.

FDA feedback supports the development of enobosarm in combination with GLP-1 RA for obesity treatment. Two regulatory pathways are outlined based on incremental weight loss. Enobosarm has potential benefits for muscle preservation and physical function. The drug may address concerns related to bone mineral density in older patients with obesity.

The Phase 2b PLATEAU clinical study will assess enobosarm’s impact on weight, body composition, and physical function in older obese patients initiating semaglutide treatment. The trial’s design includes a placebo-controlled study with key endpoints focused on weight reduction and muscle preservation. An interim analysis is expected in Q1 2027.

Veru’s financial summary for Q1 FY2026 shows positive trends, with decreased operating expenses and a net loss reduction. The company’s balance sheet indicates healthy cash reserves. Veru’s focus on innovative medicines for cardiometabolic and inflammatory diseases, such as enobosarm and sabizabulin, is highlighted in their corporate update.

Investors and media can access more information about Veru Inc. through their website. The company’s commitment to developing novel treatments for obesity and related conditions is reflected in their ongoing clinical trials and financial performance. For inquiries, contact Samuel Fisch, Executive Director of Investor Relations and Corporate Communications.

Read more at GlobeNewswire: Veru Reports Fiscal 2026 First Quarter Financial Results